Table 1.
Demographics and disease characteristics of mild- and severe-AS patients*.
| Mild-AS (n = 171) | Severe-AS (n = 64) | P value | |
|---|---|---|---|
| Male, n (%) | 83 (48.5) | 55 (85.9) | <0.001 |
| Age, years | 38.7±9.4 | 51.2±9.8 | <0.001 |
| Disease duration, years | 14.1±4.8 | 23.0±8.5 | <0.001 |
| Ever-smoked n (%) | 42 (24.6) | 24 (37.5) | 0.049 |
| HLA-B27 positivity, n (%) | 95 (55.6) | 47 (73.4) | 0.013 |
| Enthesitis, n (%) | 44 (25.7) | 19 (29.7) | 0.543 |
| Peripheral arthritis, n (%) | 75 (43.9) | 31 (48.4) | 0.531 |
| Coxofemoral joint involvement, n (%) | 35 (20.5) | 26 (40.6) | 0.002 |
| Uveitis, n (%) | 20 (11.7) | 17 (26.6) | 0.005 |
| TNFi ever-used, n (%) | 64 (37.4) | 43 (67.2) | <0.001 |
| NSAID current users, n (%) | 81 (47.4) | 27 (42.2) | 0.540 |
| ESR, mm/h, median (IQR) | 20 (12-34) | 30 (15.7-48) | 0.005 |
| CRP, mg/L, median (IQR) | 5 (3.4-9.2) | 9.6 (3.6-20.1) | <0.001 |
| mSASSS (0-72) | 0 | 48.5±17.8 | <0.001 |
* Values are presented as mean±SD, unless indicated otherwise. AS= Ankylosing spondylitis; TNFi= TNF inhibitor; NSAID= Nonsteroidal anti-inflammatory drugs; ESR= Erythrocyte sedimentation rate; CRP= C-reactive protein; mSASSS= modified Stokes AS spinal score.